NPM1 and acute myeloid leukemia: Similarly, promising clinical results of the AZA + venetoclax combination for the treatment of MRD positivity in young patients with NPM1-mutated AML have been published [87], while the results of the GIMEMA group’s clinical trial testing this hypothesis are pending publication [88].